{"id":70789,"date":"2026-05-12T11:08:40","date_gmt":"2026-05-12T11:08:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70789"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ahk-cu","status":"publish","type":"product","link":"https:\/\/medsbase.com\/de\/product\/ahk-cu\/","title":{"rendered":"AHK-Cu"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Kurze Antwort \u2014 Was ist AHK-Cu?<\/h3>\n<p style=\"margin: 0;\"><strong>AHK-Cu<\/strong> (Alanyl-Histidyl-Lysin-Kupfer(II)-Komplex) ist ein synthetisches kupferbindendes Tripeptid und das Schwestermolek\u00fcl von <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a>. While GHK-Cu is the canonical skin and wound-healing copper peptide, AHK-Cu&#8217;s signal is concentrated in <strong>Haarfollikelbiologie<\/strong> \u2014 published preclinical work documents stimulation of dermal papilla cells, follicular enlargement, increased follicular vascularization, and prolongation of the anagen growth phase. Supplied in 20\u00a0mg and 50\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Was Sie bei MedsBase erhalten:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/de\/reviews\/\">Kundenbewertungen<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Jede Bestellung ist durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> abgedeckt \u2014 wenn Ihr Paket nicht innerhalb von 20 Werktagen ankommt, versenden wir es erneut.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Spezifikation<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS-Nummer<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">110374-12-4 (AHK-Cu); 71567-06-1 (AHK freies Peptid)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekularformel<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>15<\/sub>H<sub>25<\/sub>CuN<sub>6<\/sub>O<sub>4<\/sub> (1:1 Kupferkomplex)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~417 Da (Kupferkomplex)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenz<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Ala-His-Lys (AHK, 3 Aminos\u00e4uren) koordiniert an ein einzelnes Cu<sup>2+<\/sup> Ion \u00fcber das Imidazol-Stickstoffatom von His, das Amino-Terminus von Ala und das deprotonierte Peptid-Stickstoffatom zwischen Ala und His<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisierter Kupfer-Peptid-Komplex (blaues bis blau-violettes Pulver; die Farbe stammt von den d-d-\u00dcberg\u00e4ngen des gebundenen Cu<sup>2+<\/sup>)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Reinheit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC-best\u00e4tigt, COA auf Anfrage)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Lagerung<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat: 2\u20138 \u00b0C (K\u00fchlschrank) f\u00fcr Arbeitsvorrat; \u221220 \u00b0C zur Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituiert: 2\u20138 \u00b0C, innerhalb von ~30 Tagen verwenden. Vor Licht sch\u00fctzen. Die rekonstituierte L\u00f6sung nicht einfrieren und auftauen.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>L\u00f6slichkeit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatisches Wasser (empfohlen) oder steriles Wasser f\u00fcr k\u00fcrzere Anwendungszeitr\u00e4ume. In Wasser l\u00f6slich; die gel\u00f6ste L\u00f6sung beh\u00e4lt die charakteristische blaue Farbe des gebundenen Cu<sup>2+<\/sup>.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Was ist AHK-Cu?<\/h2>\n<p><strong>AHK-Cu<\/strong> (Alanyl-Histidyl-Lysin-Kupfer(II)-Komplex) ist ein synthetisches kupferbindendes Tripeptid, das aus den drei Aminos\u00e4uren Ala, His und Lys besteht, die an ein einzelnes Cu<sup>2+<\/sup> Ion koordiniert sind. Es ist das Schwestermolek\u00fcl des ausf\u00fchrlicher untersuchten <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> \u2014 both belong to the &#8220;copper peptide&#8221; class, both share the same Cu-coordination architecture using a histidine residue, and both are studied in dermatological contexts. Where they diverge is in primary signal: GHK-Cu is the canonical peptide for skin remodelling, wound healing, and connective-tissue repair, while AHK-Cu&#8217;s most-cited applications are in <strong>Haarfollikelbiologie<\/strong>. The well-characterised molecular composition is C<sub>15<\/sub>H<sub>25<\/sub>CuN<sub>6<\/sub>O<sub>4<\/sub>, Molekulargewicht etwa 417 Da. Das Cu<sup>2+<\/sup> ion coordinates with the tripeptide via the imidazole nitrogen of histidine, the amino terminus of alanine, and the deprotonated peptide nitrogen between Ala and His \u2014 the same square-planar coordination geometry as in GHK-Cu. The bound copper gives both compounds their characteristic blue-to-violet colour in solid and dissolved form \u2014 users reconstituting AHK-Cu should expect a visibly blue working solution. AHK-Cu is supplied as a high-purity lyophilized copper-peptide complex for reconstitution with bacteriostatic water. The compound is <strong>nicht zugelassen<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sister skin-studies copper peptide, see our <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> Produktseite. <\/p>\n<h2>Wirkmechanismus \u2013 Kupferlieferung an Haarfollikel-Papillenzellen<\/h2>\n<p>Was AHK-Cu unter den Kupferpeptiden mechanistisch auszeichnet, ist seine <strong>bevorzugte Signalgebung an dermale Papillenzellen<\/strong> in the hair follicle \u2014 the mesenchymal cells at the base of each follicle that regulate hair-shaft production and cycle through the growth (anagen), regression (catagen), and rest (telogen) phases. Published studies has documented three principal mechanisms:<\/p>\n<ul>\n<li><strong>Kupferlieferung an dermale Papillenzellen<\/strong> \u2013 Das Cu<sup>2+<\/sup> ion is the active payload of AHK-Cu (and of GHK-Cu in skin studies). The tripeptide is a vehicle that ferries the metal ion into target tissue, where copper participates in multiple enzyme cofactor roles including lysyl oxidase (collagen and elastin cross-linking) and superoxide dismutase (oxidative-stress buffering). At the hair follicle, dermal papilla cells take up copper from AHK-Cu and use it to support the follicular extracellular matrix and oxidative-stress management that anagen requires.<\/li>\n<li><strong>VEGF-Hochregulierung und follikul\u00e4re Vaskularisierung<\/strong> \u2013 AHK-Cu stimuliert die Expression des vaskul\u00e4ren endothelialen Wachstumsfaktors (VEGF) in dermalen Papillenzellen. Der nachgelagerte Effekt ist eine erh\u00f6hte follikul\u00e4re Perfusion \u2013 das Wachstum neuer Kapillaren an der Follikelbasis, das den metabolischen Anforderungen der sich schnell proliferierenden Haarmatrix-Keratozyten w\u00e4hrend der Anagenphase gerecht wird. Dieser Perfusionsverbesserungsmechanismus \u00fcberschneidet sich mit dem Minoxidil-Mechanismus, arbeitet jedoch \u00fcber einen grundlegend anderen Weg (direkte Kupfer-Peptid-Signalgebung statt ATP-sensitiver Kaliumkanalmodulation).<\/li>\n<li><strong>Verl\u00e4ngerung der Anagenphase und Vergr\u00f6\u00dferung des Follikels<\/strong> \u2014 In published rodent hair-cycle studies, AHK-Cu administration prolongs the duration of the anagen growth phase and increases overall follicular size. The combined effect is more hair-shaft production per follicle per cycle. The mechanism appears to be downstream of the copper-delivery and VEGF-upregulation steps \u2014 healthy, well-perfused follicles in a copper-replete environment sustain anagen for longer before transitioning to catagen.<\/li>\n<\/ul>\n<p>The mechanism is fundamentally different from the two FDA-approved hair-loss compounds: finasteride blocks 5-alpha-reductase to lower scalp DHT (hormonal mechanism); minoxidil opens ATP-sensitive potassium channels to vasodilate follicular vessels (vascular mechanism). AHK-Cu provides direct mesenchymal-cell signalling and copper-cofactor delivery, working at a different point in follicular biology than either FDA-approved compound \u2014 which makes it a useful tool for dissecting follicular cell biology independent of androgen-axis or vasodilation-mediated mechanisms. Subcutaneous, topical, and intrafollicular injection routes are all documented in published studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AHK-Cu is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Hair follicle biology studies<\/strong> \u2014 dermal papilla cell proliferation assays, follicular size measurement, hair-shaft diameter analysis, organ-cultured hair follicle studies; canonical copper-peptide compound for the hair-axis (Pyo et al., J Korean Med Sci 2007; Uno &amp; Kurata, J Investig Dermatol)<\/li>\n<li><strong>Hair cycle studies<\/strong> \u2014 Anagen-\/Katagen-\/Telogen-Phasendauer, Anagen-Induktion in Telogen-Follikeln, vergleichende Dosis-Wirkungs-Beziehung mit etablierten Haarachsen-Vergleichsverbindungen<\/li>\n<li><strong>Follicular vascularization studies<\/strong> \u2014 VEGF-Expression, Kapillardichte an der Follikelbasis, peri-follikul\u00e4re Perfusionsmessung<\/li>\n<li><strong>Comparative copper peptide studies<\/strong> \u2014 direkter Vergleich mit <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> for dermatological studies; AHK-Cu favoured for hair-axis endpoints, GHK-Cu favoured for skin\/wound\/anti-aging endpoints<\/li>\n<li><strong>Topical and intradermal formulation studies<\/strong> \u2014 AHK-Cu is one of the more-studied copper peptides for topical and intradermal delivery; published studies investigates skin-penetration depth, follicular targeting via different vehicle formulations<\/li>\n<li><strong>Haarausfallmechanismus-Analyse<\/strong> \u2014 alongside finasteride (androgen-axis) and minoxidil (vascular axis), AHK-Cu provides a third orthogonal studies mechanism (mesenchymal-cell + copper-cofactor + VEGF axis); useful for mechanism-of-action studies designs<\/li>\n<li><strong>Collagen and elastin studies<\/strong> \u2014 copper&#8217;s role as cofactor for lysyl oxidase makes copper peptides relevant to studies on extracellular matrix crosslinking; AHK-Cu shares this mechanism with GHK-Cu at the broader level although hair-axis effects predominate.<\/li>\n<\/ul>\n<p>For broader context on where AHK-Cu fits within the copper-peptide and dermatological studies landscape, see <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> as the canonical skin-studies copper peptide, <a href=\"https:\/\/medsbase.com\/de\/bpc-157\/\">BPC-157<\/a> for tissue-repair studies, and <a href=\"https:\/\/medsbase.com\/de\/tb-500\/\">TB-500<\/a> for systemic recovery. Browse the full <a href=\"https:\/\/medsbase.com\/de\/peptides\/\">Peptid-Katalog<\/a> f\u00fcr verwandte Verbindungen. <\/p>\n<h2>Verf\u00fcgbare St\u00e4rken und Konzentrationen<\/h2>\n<p>MedsBase stocks AHK-Cu in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial-St\u00e4rke<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typischer Anwendungsfall<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Packungsgr\u00f6\u00dfen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>20 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 topical formulation and short-cycle protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Bulk packs vial, extended cycles, lowest per-mg cost, multi-cohort follicle studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized copper-peptide complex, 99%+ HPLC purity). Higher-mg vials are particularly useful for AHK-Cu because of the relatively large doses typical in topical-formulation studies compared with the microgram-range systemic peptides. Higher-mg vials require smaller reconstitution volumes per unit dose. <\/p>\n<h2>Vergleich \u2013 AHK-Cu vs GHK-Cu<\/h2>\n<p>AHK-Cu und <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> are sister copper-binding tripeptides that share the same Cu-coordination chemistry but differ in the first amino-acid residue (Ala vs Gly). This minor structural difference produces qualitatively different signals: GHK-Cu dominates skin\/wound\/anti-aging studies while AHK-Cu&#8217;s strongest signal is in hair follicle biology. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kriterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AHK-Cu<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">GHK-Cu<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>L\u00e4nge<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 Aminos\u00e4uren (Tripeptid)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 Aminos\u00e4uren (Tripeptid)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sequenz<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ala-His-Lys<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Gly-His-Lys<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Kupferkoordination<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1:1 Cu<sup>2+<\/sup> \u00fcber His + N-Terminus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1:1 Cu<sup>2+<\/sup> \u00fcber His + N-Terminus<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Haarfollikelbiologie, Anagenverl\u00e4ngerung<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hautumbau, Wundheilung, Anti-Aging<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Zielzelltyp<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dermale Papillenzellen (Haarfollikel)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dermale Fibroblasten, Keratinozyten (Haut)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>VEGF-Signalweg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Stark \u2013 follikul\u00e4re Vaskularisierung<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00e4\u00dfig \u2013 Angiogenese im Wundbett<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Endogenes Vorkommen<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Synthetisch (kein signifikanter endogener Pool)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Endogen (nimmt mit dem Alter im Plasma ab)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typische Dosis<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201310 mg topisch \/ 1\u20135 mg subkutan<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20135 mg topisch \/ 0,5\u20132 mg subkutan<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For hair-axis studies, AHK-Cu is the canonical first choice because of the dermal-papilla-cell selectivity and the documented anagen-prolongation signal. For skin remodelling, wound healing, and anti-aging studies, <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> is the canonical reference. Some studies designs use both in parallel arms to dissect copper-peptide effects that are shared (general Cu cofactor delivery) from effects that are sequence-specific (cell-type selectivity). <\/p>\n<h2>Lagerung und Rekonstitution<\/h2>\n<p><strong>Vor der Rekonstitution:<\/strong> Lagern Sie lyophilisierte Fl\u00e4schchen im K\u00fchlschrank bei 2\u20138 \u00b0C in der Originalverpackung f\u00fcr kurzfristige Arbeitsvorr\u00e4te. F\u00fcr unge\u00f6ffnete Langzeitlagerung frieren Sie bei \u221220 \u00b0C ein. Lyophilisiertes AHK-Cu ist im K\u00fchlschrank bis zu 24 Monate und bei \u221220 \u00b0C bis zu 36 Monate stabil. Vermeiden Sie Gefrier-Auftau-Zyklen bei dem lyophilisierten Pulver. Die Cu<sup>2+<\/sup> Koordination ist in der lyophilisierten Form stabil; sobald rekonstituiert, kann eine l\u00e4ngere Exposition gegen\u00fcber Licht oder Reduktionsmitteln den Kupferoxidationszustand beeinflussen. <strong>Rekonstitutionsverfahren:<\/strong> Injizieren Sie bakterostatisches Wasser an die Seitenwand des Peptidfl\u00e4schchens (nicht direkt auf den lyophilisierten Kuchen). Bei einem 20 mg Fl\u00e4schchen ergibt 2,0 mL bakterostatisches Wasser eine Arbeitskonzentration von 10 mg\/mL \u2014 0,1 mL liefert 1 mg; 0,5 mL liefert 5 mg. Schwenken Sie vorsichtig \u2014 nicht <strong>nicht<\/strong> sch\u00fctteln \u2014 und lassen Sie 2\u20135 Minuten f\u00fcr die vollst\u00e4ndige Aufl\u00f6sung. Eine korrekt rekonstituierte L\u00f6sung sollte klar sein mit der charakteristischen blauen Farbe des gebundenen Cu<sup>2+<\/sup>. Tr\u00fcbung oder Ausf\u00e4llung weisen auf ein Problem bei der Rekonstitution hin; verwerfen Sie die L\u00f6sung und versuchen Sie es erneut. <strong>gek\u00fchlt bei 2\u20138 \u00b0C lagern und innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren.<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity. Protect from direct light at all times. For topical formulation studies, AHK-Cu can be incorporated into a wide range of vehicles (creams, gels, serums) for follicle-studies delivery; published vehicle studies includes liposomal and microemulsion formulations for enhanced follicular penetration. <\/p>\n<h2 id=\"faqs\">H\u00e4ufig gestellte Fragen<\/h2>\n<h3>What is AHK-Cu used for in studies?<\/h3>\n<p>AHK-Cu is used in studies investigating hair follicle biology, dermal papilla cell proliferation, anagen phase prolongation, follicular vascularization, hair-shaft diameter, comparative copper-peptide pharmacology, topical and intradermal formulation studies, and mechanism-of-action dissection of hair-loss biology distinct from the androgen-axis (finasteride) and vascular (minoxidil) mechanisms. It is the canonical copper-peptide compound for the hair-axis. The pharmaceutical-grade AHK-Cu sold here is <strong>nicht<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Wie unterscheidet sich AHK-Cu von GHK-Cu?<\/h3>\n<p>Beide sind kupferbindende Tripeptide, die dieselbe Cu-Koordinationsarchitektur aufweisen (His-vermittelte 1:1 Cu<sup>2+<\/sup> binding). They differ in the first amino-acid residue \u2014 alanine in AHK-Cu, glycine in GHK-Cu \u2014 producing different cell-type selectivity in published studies. AHK-Cu&#8217;s strongest signal is in dermal papilla cells of the hair follicle; <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a>\u2018Das st\u00e4rkste Signal von \u2018s liegt in Hautfibroblasten und Keratinozyten. Die beiden werden oft parallel untersucht, um gemeinsame Kupferpeptid-Effekte von sequenzspezifischen Effekten zu unterscheiden. <\/p>\n<h3>What is the typical AHK-Cu dose?<\/h3>\n<p>Published preclinical protocols typically use 1\u20135\u00a0mg per administration for subcutaneous delivery and 2\u201310\u00a0mg for topical formulation studies, given 1\u20133 times daily for 4\u201312 week cycles. A 20\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 10\u00a0mg\/mL \u2014 0.1\u00a0mL equals 1\u00a0mg, 0.5\u00a0mL equals 5\u00a0mg. <\/p>\n<h3>Nein. AHK-Cu ist nicht von der FDA, EMA, MHRA oder einer anderen gro\u00dfen Regulierungsbeh\u00f6rde f\u00fcr die therapeutische Anwendung beim Menschen zugelassen. Kupferpeptide wurden in einigen kosmetischen Produkten unter kosmetischen Regulierungsrahmen verwendet, aber AHK-Cu hat speziell keine therapeutische Zulassung. Alle von Forschungsanbietern verkauften AHK-Cu-Produkte sind f\u00fcr Laboruntersuchungen bestimmt und sollten nicht an Menschen verabreicht werden.<\/h3>\n<p>No. AHK-Cu is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Copper peptides have been incorporated into some cosmetic products under cosmetic-regulation frameworks, but AHK-Cu specifically has no therapeutic approval. <\/p>\n<h3>Lyophilisierte Fl\u00e4schchen: gek\u00fchlt bei 2\u20138 \u00b0C f\u00fcr kurzfristige Arbeitsvorr\u00e4te oder bei \u221220 \u00b0C f\u00fcr die Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituierte L\u00f6sung: gek\u00fchlt bei 2\u20138 \u00b0C, innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren \u2013 Gefrier-Tau-Zyklen degradieren das Peptid und k\u00f6nnen die Kupferkoordination beeintr\u00e4chtigen. Sch\u00fctzen Sie es jederzeit vor direktem Licht, um den Kupferoxidationszustand zu erhalten.<\/h3>\n<p>Lyophilisierte Fl\u00e4schchen: bei 2\u20138 \u00b0C gek\u00fchlt lagern f\u00fcr kurzfristige Arbeitsvorr\u00e4te oder bei \u221220 \u00b0C f\u00fcr Langzeitlagerung unge\u00f6ffneter Fl\u00e4schchen. Rekonstituierte L\u00f6sung: bei 2\u20138 \u00b0C gek\u00fchlt lagern, innerhalb von 30 Tagen verwenden. Rekonstituierte L\u00f6sung nicht einfrieren \u2013 Gefrier-Tau-Zyklen degradieren das Peptid und k\u00f6nnen die Kupferkoordination beeintr\u00e4chtigen. Immer vor direktem Licht sch\u00fctzen, um den Kupferoxidationszustand zu erhalten. <\/p>\n<h3>Sch\u00fctteln Sie das Fl\u00e4schchen. Eine korrekt rekonstituierte L\u00f6sung ist klar mit der charakteristischen blauen Farbe des gebundenen Cu.<\/h3>\n<p>Befolgen Sie das oben beschriebene Rekonstitutionsverfahren. Geben Sie bakterienstatisches Wasser an der Seitenwand des Fl\u00e4schchens hinzu (nicht auf den lyophilisierten Kuchen), schwenken Sie vorsichtig und lassen Sie 2\u20135 Minuten zur vollst\u00e4ndigen Aufl\u00f6sung. Sch\u00fctteln Sie <strong>nicht<\/strong> Sch\u00fctteln Sie das Fl\u00e4schchen. Eine korrekt rekonstituierte L\u00f6sung ist klar mit der charakteristischen blauen Farbe des gebundenen Cu<sup>2+<\/sup> \u2014 die Farbe selbst best\u00e4tigt die erfolgreiche Rekonstitution und intakte Kupferkoordination. Bei einer 20 mg-Vial + 2,0 mL Verd\u00fcnnungsmittel betr\u00e4gt die Arbeitskonzentration 10 mg\/mL. <\/p>\n<h3>Welche St\u00e4rken f\u00fchrt MedsBase?<\/h3>\n<p>MedsBase carries AHK-Cu in 20\u00a0mg and 50\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Warum ist AHK-Cu blau gef\u00e4rbt?<\/h3>\n<p>Die charakteristische blau-violette Farbe von AHK-Cu (und GHK-Cu) stammt von den d-d-Elektronen\u00fcberg\u00e4ngen des gebundenen Cu<sup>2+<\/sup> in der quadratisch-planaren Koordinationsumgebung, die durch das Histidinrest und das Peptidr\u00fcckgrat gebildet wird. Die Farbe ist ein n\u00fctzlicher qualitativer Indikator f\u00fcr eine erfolgreiche Kupferkoordination \u2014 eine richtig rekonstituierte blaue L\u00f6sung best\u00e4tigt intaktes Cu<sup>2+<\/sup> Bindung, w\u00e4hrend eine farblose oder blasse L\u00f6sung auf Kupferverlust oder Abbau hinweisen w\u00fcrde. Dies ist einzigartig unter kleinen Peptiden \u2014 die meisten synthetischen Peptide ergeben bei der Rekonstitution farblose L\u00f6sungen. <\/p>\n<h3>Wie verh\u00e4lt sich AHK-Cu im Vergleich zu Finasterid oder Minoxidil?<\/h3>\n<p>The three target hair-loss biology through completely different mechanisms. Finasteride blocks 5-alpha-reductase to lower scalp dihydrotestosterone (DHT) levels \u2014 an androgen-axis mechanism. Minoxidil opens ATP-sensitive potassium channels to vasodilate follicular vessels \u2014 a vascular mechanism. AHK-Cu provides direct copper-cofactor delivery and VEGF-mediated follicular vascularization at the dermal papilla cell level \u2014 a mesenchymal-cell mechanism. The three mechanisms are orthogonal, which makes AHK-Cu a useful tool for studying follicular biology independent of androgen-axis or vasodilation-mediated effects. <\/p>\n<h3>Does AHK-Cu cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses, with the main on-target effect being follicular stimulation. Off-target findings can include local injection-site irritation and (with prolonged high-dose topical exposure) modest cutaneous discolouration from copper deposition \u2014 both reversible with discontinuation. Systemic adverse effects from topical applications are rare due to limited transcutaneous absorption. <\/p>\n<h3>Was ist die Halbwertszeit von AHK-Cu?<\/h3>\n<p>In preclinical studies, AHK-Cu has a relatively short plasma half-life (~1\u20132 hours) following subcutaneous administration. The short half-life is offset by retention of bound copper in target tissues \u2014 even after plasma clearance, the copper delivered to dermal papilla cells continues to support follicular biology through its enzyme-cofactor roles. Topical formulations provide sustained local exposure that is more relevant for hair-axis studies than the systemic plasma profile. <\/p>\n<h3>Can AHK-Cu and GHK-Cu be stacked in studies?<\/h3>\n<p>Yes. The two copper peptides target different cell types (dermal papilla for AHK-Cu, dermal fibroblasts for GHK-Cu) and address different studies domains (hair vs skin), so co-administration is not pharmacologically redundant. Study protocols studying combined skin-and-hair endpoints \u2014 for example, comprehensive dermatological remodelling studies \u2014 sometimes use both arms. <\/p>\n<h3>How long does AHK-Cu take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on dermal papilla cell VEGF expression are detectable within 24\u201372 hours in cell-culture studies. Follicular size and anagen-prolongation effects in rodent hair-cycle models typically become statistically significant after 4\u20138 weeks of regular treatment and continue to accrue through 12\u201316 weeks \u2014 matching the natural hair-cycle timeframe. <\/p>\n<h3>Kann ich AHK-Cu f\u00fcr den internationalen Versand bestellen?<\/h3>\n<p>Ja. MedsBase versendet AHK-Cu weltweit \u00fcber unser spezielles Peptid-Versandnetzwerk. Bestellungen, die ausschlie\u00dflich Peptide enthalten, qualifizieren sich f\u00fcr unseren eigenst\u00e4ndigen Peptid-Versandservice. Alle Bestellungen werden in temperaturkontrollierter Verpackung mit vollst\u00e4ndiger Sendungsverfolgung versandt und sind durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Hair, Skin, and Tissue-Regeneration Studies<\/h2>\n<ul>\n<li><a href=\"\/de\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Sister copper-binding tripeptide \u2014 canonical skin remodelling and wound-healing compound<\/li>\n<li><a href=\"\/de\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 tissue-regeneration and recovery<\/li>\n<li><a href=\"\/de\/tb-500\/\"><strong>TB-500 (Thymosin Beta-4)<\/strong><\/a> \u2014 Systemic healing fragment \u2014 tissue and vascular recovery<\/li>\n<li><a href=\"\/de\/epitalon\/\"><strong>Epitalon<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 longevity and circadian rhythm support<\/li>\n<li><a href=\"\/de\/semax\/\"><strong>Semax<\/strong><\/a> \u2014 Nootropic heptapeptide \u2014 CNS compound<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Weiterf\u00fchrende Literatur<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the copper-peptide studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Durchst\u00f6bern Sie das gesamte Sortiment <a href=\"https:\/\/medsbase.com\/de\/peptides\/\"><strong>Peptid-Katalog<\/strong><\/a>, mit verwandten dermatologischen und geweberegenerierenden Verbindungen einschlie\u00dflich <a href=\"https:\/\/medsbase.com\/de\/ghk-cu\/\">GHK-Cu<\/a> (sister copper peptide for skin studies), <a href=\"https:\/\/medsbase.com\/de\/bpc-157\/\">BPC-157<\/a> (Geweberegeneration) und <a href=\"https:\/\/medsbase.com\/de\/tb-500\/\">TB-500<\/a> (systemische Heilung).<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Alanyl-Histidyl-Lysin Kupfer(II)-Tripeptid<br \/>\n\u2705 Schwestermolek\u00fcl zu GHK-Cu<br \/>\n\u2705 Hair follicle biology compound<br \/>\n\u2705 Stimulation der dermalen Papillenzellen, Verl\u00e4ngerung der Anagenphase<br \/>\n\u2705 Orthogonal zu Finasterid\/Minoxidil-Mechanismen<\/p>\n<p><strong>AHK-Cu<\/strong> enth\u00e4lt einen synthetischen Kupfer-Peptid-Komplex.<\/p>","protected":false},"featured_media":70940,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6290,5441],"class_list":["post-70789","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-ahk-cu","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product\/70789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/comments?post=70789"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media\/70940"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media?parent=70789"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_brand?post=70789"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_cat?post=70789"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_tag?post=70789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}